in?Diabetes?(WHO?MSVDD) participants from ten centres was carried out,?causes of death?were ascertained and age-adjusted?mortality?rates were calculated by centre, sex and type of?diabetes. Excessmortality, compared with the background population, was assessed in terms of standardised?mortality?
The predominant benefit in terms of the combined endpoint was powered by a 24% reduction in the rate of adjudicated (first) hospitalizations for worsening HF as a first event in those receiving valsartan versus placebo (13.8% vs. 18.2% p 0.001). The other primary endpoint of all-cause ...
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Share and Cite MDPI and ACS Style Krzesińska, A.; Marlęga-Linert, J.; Chyła-Danił, G.; Marcin...